Pakistan approves Chinese anti-COVID vaccine Sinopharm for emergency use

DRAP approved the vaccine on Monday, two days after it had approved the emergency use of Oxford-AstraZeneca COVID-19 vaccine.

Agencies
Pakistan has already pre-booked 1.1 million doses of Sinopharm's COVID-19 vaccine and the process of its import will start soon.
Pakistan authorities have approved the Chinese Sinopharm COVID-19 vaccine for emergency use in the country as the nation continues to witness a surge in the number of coronavirus infections.

The Drug Regulatory Authority of Pakistan (DRAP) approved the vaccine on Monday, two days after it had approved the emergency use of Oxford-AstraZeneca COVID-19 vaccine.

Dr Asim Rauf, the DRAP chief executive officer, while talking said the National Institute of Health (NIH) got the Sinopharm's vaccine registered on its name.


"The approval has been given for emergency use and it will pave the way for bringing the vaccine to Pakistan," he was quoted as saying to the Dawn newspaper.

Pakistan has already pre-booked 1.1 million doses of Sinopharm's COVID-19 vaccine and the process of its import will start soon.

Till Tuesday, Pakistan has reported 11,055 deaths due to coronavirus, reported the ministry of National Health Services.
ADVERTISEMENT

It showed that the number of positive cases has surged to 523,011 after 1,800 persons tested positive for COVID-19 in the past 24 hours.

Meanwhile, Pakistan Medical Association, a representative body of doctors in the nation, has asked the government to share details of the vaccines which are under consideration for import as well as their efficacy rates.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+